Program
abemaciclib
Also written as “Abemaciclib”, “LY2835219” and “Abemaciclib Tablet (Test Formulation)”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Neoplasm Metastasis · Sarcoma, Ewing, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 4814 open or running | phase 4since Jun 12, 2019 | Jul 12, 2011 | Nov 2026phase 1 · NCT07818967 |
| Hoffmann-La Roche | 10 open or running | phase 2since Sep 11, 2017 | Sep 11, 2017 | none ahead |
Also a collaborator on its studies: Bayer and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 35 studies since Jul 12, 2011.
- Jun 12, 2019Phase 4 study in Breast NeoplasmsEli Lilly · NCT03988114 · United States, Argentina, Austria and more
- Jul 23, 2019Phase 4 study in Breast NeoplasmsEli Lilly · NCT04031885 · 4 enrolled · United States, Puerto Rico
- Aug 26, 2019Phase 1 study in Advanced CancerEli Lilly · NCT04071262 · 6 enrolled · Japan
- Jan 22, 2020Phase 2 study in Sarcoma, EwingEli Lilly · NCT04238819 · 47 enrolled · United States, Australia, Belgium and more
- May 28, 2020Phase 2 study in Metastatic Castration-Resistant Prostate CancerEli Lilly · NCT04408924 · 44 enrolled · United States, France, Spain
- Jan 12, 2021Phase 4 study in Breast NeoplasmsEli Lilly · NCT04707196 · 200 enrolled · India
- Feb 11, 2021Phase 3 study in Breast NeoplasmsEli Lilly · NCT04752332 · 111 enrolled · United States, Argentina, Australia and more
- Dec 22, 2021Phase 3 study in Breast NeoplasmsEli Lilly · NCT05169567 · 368 enrolled · United States, Argentina, Belgium and more
- Mar 10, 2022Phase 3 study in Prostatic NeoplasmsEli Lilly · NCT05288166 · 925 enrolled · United States, Argentina, Australia and more
- Jun 28, 2022Phase 2 study in Sarcoma, EwingEli Lilly · NCT05440786 · 46 enrolled · United States, Australia, France and more
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- Aug 14, 2023Phase 1 study in Prostatic NeoplasmsEli Lilly · NCT05999968 · 10 enrolled · United States, Germany, Spain
- May 9, 2024Phase 2 study in GliomaEli Lilly · NCT06413706 · 45 enrolled · United States, Australia, Belgium and more
- Aug 26, 2026Phase 1 study in Healthy VolunteersEli Lilly · NCT07818967 · 15 planned · Singapore
Ahead
- Nov 2026Primary completion: phase 1 study in Healthy VolunteersEli Lilly · NCT07818967
- Feb 2027Primary completion: phase 2 study in GliomaEli Lilly · NCT06413706
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
TargetBeta
“The mesylate salt of abemaciclib, an orally available cyclin-dependent kinase (CDK) inhibitor that targets the cyclin D1-CDK4 and cyclin D3-CDK6 cell cycle pathway, ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
Studies
All 49 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07818967Healthy Volunteers · Singapore | 1 | Recruiting | Eli Lilly | Nov 2026 | 15 |
| NCT06413706Glioma · United States, Australia, Belgium and more | 2 | Active, not recruiting | Eli Lilly | Feb 2027 | 45 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05999968Prostatic Neoplasms · United States, Germany, Spain | 1 | Terminated | Eli Lilly | Feb 23, 2024 | 10 |
| NCT05440786Sarcoma, Ewing · United States, Australia, France and more | 2 | Active, not recruiting | Eli Lilly | Jan 15, 2025 | 46 |
| NCT05288166Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Feb 15, 2024 | 925 |
| NCT05169567Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Eli Lilly | Feb 8, 2024 | 368 |
| NCT04752332Breast Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Eli Lilly | Jun 26, 2024 | 111 |
| NCT04707196Breast Neoplasms · India | 4 | Completed | Eli Lilly | Jan 9, 2023 | 200 |
| NCT04408924Metastatic Castration-Resistant Prostate Cancer · United States, France, Spain | 2 | Completed | Eli Lilly | Apr 27, 2022 | 44 |
| NCT04238819Sarcoma, Ewing · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Mar 15, 2024 | 47 |
| NCT04071262Advanced Cancer · Japan | 1 | Completed | Eli Lilly | Feb 12, 2021 | 6 |
| NCT04031885Breast Neoplasms · United States, Puerto Rico | 4 | Terminated | Eli Lilly | Aug 11, 2020 | 4 |
| NCT03988114Breast Neoplasms · United States, Argentina, Austria and more | 4 | Withdrawn | Eli Lilly | Mar 23, 2022 | 0 |
| NCT03703466Breast Neoplasms · Australia, Belgium, Russian Federation and more | 2 | Completed | Eli Lilly | Jul 29, 2019 | 72 |
| NCT03706365Prostatic Neoplasms · United States, Australia, China and more | 3 | Active, not recruiting | Eli Lilly | Jan 2, 2024 | 393 |
| NCT03280563Breast Neoplasms · United States, Israel, South Korea | 2 | Completed | Hoffmann-La Roche | Sep 26, 2024 | 144 |
| NCT03155997Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Mar 16, 2020 | 5,637 |
| NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Apr 20, 2018 | 106 |
| NCT02919696Neoplasm Metastasis · China | 1 | Completed | Eli Lilly | Nov 23, 2018 | 26 |
| NCT02884089Healthy · United States | 1 | Completed | Eli Lilly | Dec 2016 | 40 |
| NCT02779751Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 1 | Active, not recruiting | Eli Lilly | Feb 3, 2020 | 100 |
| NCT02763566Breast Neoplasms · Brazil, China, India and more | 3 | Active, not recruiting | Eli Lilly | Mar 29, 2019 | 463 |
| NCT02747004Breast Neoplasms · United States, Argentina, Austria and more | 2 | Completed | Eli Lilly | Jun 15, 2018 | 234 |
| NCT02745769Colorectal Neoplasms · United States, France, United Kingdom | 1 | Completed | Eli Lilly | Nov 5, 2018 | 23 |
| NCT02688088Neoplasm Metastasis · United States | 1 | Completed | Eli Lilly | Feb 4, 2018 | 48 |
| NCT02677844Healthy · United States | 1 | Completed | Eli Lilly | Jul 2016 | 35 |
| NCT02675231Hormone Receptor Positive Breast Cancer · United States, Argentina, Australia and more | 2 | Completed | Eli Lilly | Apr 8, 2019 | 237 |
| NCT02672423Healthy · United States | 1 | Completed | Eli Lilly | Oct 2016 | 127 |
| NCT02482935Healthy · United States | 1 | Completed | Eli Lilly | Sep 2015 | 30 |
| NCT02450539Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Completed | Eli Lilly | Mar 31, 2017 | 159 |
| NCT02441946Breast Neoplasms · United States, Austria, Belgium and more | 2 | Completed | Eli Lilly | Aug 16, 2016 | 224 |
| NCT02411591Carcinoma, Non-Small-Cell Lung · Belgium, France, Spain | 1 | Completed | Eli Lilly | Jun 23, 2017 | 66 |
| NCT02387814Hepatic Insufficiency · United States | 1 | Completed | Eli Lilly | Aug 2015 | 35 |
| NCT02327143Healthy Volunteers · United Kingdom | 1 | Completed | Eli Lilly | Feb 2015 | 11 |
| NCT02308020Breast Neoplasms · United States, Australia, Austria and more | 2 | Completed | Eli Lilly | Nov 8, 2018 | 162 |
| NCT02256267Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Nov 2014 | 24 |
| NCT02246621Breast Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Eli Lilly | Jan 31, 2017 | 493 |
| NCT02152631Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more | 3 | Active, not recruiting | Eli Lilly | Sep 15, 2017 | 453 |
| NCT02117648Neoplasms · United States | 1 | Completed | Eli Lilly | Feb 2015 | 26 |
| NCT02107703Breast Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Eli Lilly | Feb 14, 2017 | 669 |
| NCT02102490Breast Neoplasms · United States, Belgium, France and more | 2 | Completed | Eli Lilly | Apr 30, 2016 | 132 |
| NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain | 1 | Completed | Eli Lilly | May 2, 2018 | 142 |
| NCT02059148Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Aug 2014 | 24 |
| NCT02057133Breast Neoplasms · United States | 1 | Active, not recruiting | Eli Lilly | Mar 15, 2021 | 198 |
| NCT02014129Neoplasm Metastasis · Japan | 1 | Completed | Eli Lilly | Apr 1, 2015 | 12 |
| NCT01913314Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Oct 2013 | 6 |
| NCT01739309Lymphoma, Mantle-Cell · France, Germany | 2 | Completed | Eli Lilly | Sep 28, 2015 | 28 |
| NCT01394016Advanced Cancer · United States | 1 | Completed | Eli Lilly | May 29, 2014 | 225 |
How it is read
Names in the registry
- “Abemaciclib”, 41 entries
- “LY2835219”, 5 entries
- “Abemaciclib Tablet (Test Formulation)”, 2 entries
- “Abemaciclib Tablet (Reference Formulation)”, 1 entry
- “Abemaciclib Oral Granules (Test Formulation)”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Prostatic Neoplasms, 4 studies
- Neoplasm Metastasis, 4 studies
- Sarcoma, Ewing, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.